argenx SE
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
19 mei 2015 - 07:10
Statutaire naam
argenx SE
Titel
arGEN-X awarded €1.5 million IWT grant to advance the application of NHance® Fc modifications in therapeutic antibodies
Bericht
Breda, The Netherlands / Ghent, Belgium, 19 May 2015 - arGEN-X N.V. (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, today announced that it has received a € 1.5 million grant from the Institute for the Promotion of Innovation by Sciences and Technology in Flanders (IWT). This grant will be used to advance and commercialize the application of the NHance® Fc modifications in therapeutic antibodies.
Datum laatste update: 19 januari 2026